PRTC News and Press, PureTech Health plc From 11/29/23

Prescription Drug User Fee Act (PDUFA) action date is September 26, 2024 If approved, KarXT would represent the first new pharmacological approach to treating schizophrenia in several decades The application is supported by positive data from the EMERGENT clinical trial program sh...

Results demonstrate KarXT was not associated with clinically meaningful increases in blood pressure in adults with schizophrenia KarXT demonstrated a mean change from baseline to week 8 in 24-hour ambulatory systolic blood pressure of -0.59 mmHg, the primary endpoint in the trial ...

2023-11-16 17:03:01 ET More on Karuna Therapeutics Karuna Therapeutics: Rewiring The Schizophrenia Paradigm - A Novel Leap Beyond Dopamine Karuna Therapeutics, Inc. (KRTX) Q3 2023 Earnings Conference Call Transcript Karuna Therapeutics: KarXT Could Become A New Stand...

2023-11-14 14:09:36 ET More on PureTech PureTech reports 1H results Seeking Alpha’s Quant Rating on PureTech Historical earnings data for PureTech Financial information for PureTech For further details see: PureTech Phase 2 study for anti-a...

Orally administered LYT-300 achieved a statistically significant (p=0.0001) reduction in the stress hormone response, as measured by salivary cortisol, compared to placebo This proof-of-concept trial demonstrating a reduction in the physiological stress response supports the further devel...

LYT-100 demonstrated ~50% improvement versus pirfenidone in key adverse events at a comparable exposure level, which may lead to better patient compliance and improved treatment outcomes in IPF LYT-100 also demonstrated favorable tolerability at a 43% higher exposure level, supporting the...

VE202 is an orally administered, rationally-defined bacterial consortium candidate for the treatment of ulcerative colitis Vedanta’s pipeline also includes VE303 , its Phase 3 ready therapeutic candidate designed for the prevention of recurrent Clostridioides difficile infe...

Founded Entity Karuna Therapeutics submits New Drug Application to U.S. Food and Drug Administration for KarXT for the treatment of schizophrenia If approved, KarXT will be the first new mechanism in over 50 years for patients living with schizophrenia PureTech Health plc (N...

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announced the appointment of Robert Lyne as Chief Portfolio Officer. Rob...

2023-08-30 02:01:30 ET More on PureTech PureTech bags $11.4M from U.S. Department of Defense contract Vedanta Biosciences raises $106.5M to fund drug development programs Royalty Pharma, PureTech in pact for royalties in Karuna’s lead asset PureTech He...